- Page 1:
Scalable Approaches for Analysis of
- Page 5:
DeclarationThis is to certify that1
- Page 9 and 10:
AcknowledgmentThanks are due to my
- Page 11:
ContentsList of Abbreviationsxxix1.
- Page 14 and 15:
Contents8.3. Methods . . . . . . .
- Page 16 and 17:
List of Figures3.1. An illustration
- Page 18 and 19:
List of Figures5.2. Left: LOESS-smo
- Page 20 and 21:
List of Figures7.12. Top 5 principa
- Page 22 and 23:
List of FiguresB.1. APRC for HAPGEN
- Page 24 and 25:
List of FiguresC.1. Time to run fmp
- Page 26 and 27:
List of Tables6.2. List of independ
- Page 29:
List of AbbreviationsAUCFNFPGEOGiBG
- Page 32 and 33:
1. Introductionmolecular marker dat
- Page 34 and 35:
1. IntroductionThesis Outline and C
- Page 36 and 37:
1. IntroductionChapter 7 — Charac
- Page 39 and 40:
2Biological BackgroundIn this chapt
- Page 41 and 42:
2.2. The Molecular Basis for Diseas
- Page 43 and 44:
2.3. Gene Expression• mRNA extrac
- Page 45 and 46:
2.3. Gene Expressionanalyses, and s
- Page 47 and 48:
2.3. Gene Expression• Tissue spec
- Page 49 and 50:
2.3. Gene ExpressionepigeneticsDNAm
- Page 51 and 52:
REVIEWS2.4. The Genetic Basis of Di
- Page 53 and 54:
© 2010 Nature America, Inc. All ri
- Page 55 and 56:
2.4. The Genetic Basis of Diseaseth
- Page 57 and 58:
TECHNICAL REPORTS2.4. The Genetic B
- Page 59 and 60:
2.4. The Genetic Basis of Diseaseno
- Page 61 and 62:
2.4. The Genetic Basis of Diseasesa
- Page 63 and 64:
2.4. The Genetic Basis of Diseasewi
- Page 65 and 66:
3Review of the Analysis of Gene Exp
- Page 67 and 68:
3.2. Supervised Machine LearningEmp
- Page 69 and 70:
3.3. Linear Models and Loss Functio
- Page 71 and 72:
3.4. Feature Selection — Finding
- Page 73 and 74:
3.4. Feature Selection — Finding
- Page 75 and 76:
3.4. Feature Selection — Finding
- Page 77 and 78:
3.4. Feature Selection — Finding
- Page 79:
3.4. Feature Selection — Finding
- Page 82 and 83:
3. Review of the Analysis of Gene E
- Page 84 and 85:
3. Review of the Analysis of Gene E
- Page 86 and 87:
3. Review of the Analysis of Gene E
- Page 88 and 89:
4. Gene Sets for Breast Cancer Prog
- Page 90 and 91:
4. Gene Sets for Breast Cancer Prog
- Page 92 and 93:
4. Gene Sets for Breast Cancer Prog
- Page 94 and 95:
4. Gene Sets for Breast Cancer Prog
- Page 96 and 97:
4. Gene Sets for Breast Cancer Prog
- Page 98 and 99:
4. Gene Sets for Breast Cancer Prog
- Page 100 and 101:
4. Gene Sets for Breast Cancer Prog
- Page 102 and 103:
4. Gene Sets for Breast Cancer Prog
- Page 104 and 105:
4. Gene Sets for Breast Cancer Prog
- Page 106 and 107:
4. Gene Sets for Breast Cancer Prog
- Page 108 and 109:
4. Gene Sets for Breast Cancer Prog
- Page 110 and 111:
4. Gene Sets for Breast Cancer Prog
- Page 112 and 113:
4. Gene Sets for Breast Cancer Prog
- Page 114 and 115:
4. Gene Sets for Breast Cancer Prog
- Page 116 and 117:
4. Gene Sets for Breast Cancer Prog
- Page 118 and 119:
4. Gene Sets for Breast Cancer Prog
- Page 120 and 121: 4. Gene Sets for Breast Cancer Prog
- Page 122 and 123: 4. Gene Sets for Breast Cancer Prog
- Page 124 and 125: 4. Gene Sets for Breast Cancer Prog
- Page 127 and 128: 5Fast and Memory-Efficient Sparse L
- Page 129 and 130: 5.2. BackgroundThe lasso can be for
- Page 131 and 132: 5.3. Design Considerations5.3. Desi
- Page 133 and 134: 5.4. MethodsThere are two key aspec
- Page 135 and 136: 5.4. Methodssome stage during the a
- Page 137 and 138: 5.4. Methodsset convergence means t
- Page 139 and 140: 5.4. Methods5.4.6. Discrimination a
- Page 141 and 142: 5.5. Resultsdiscovery and validatio
- Page 143 and 144: 5.5. Results5.5.1. SparSNP makes po
- Page 145 and 146: 5.6. Software Featuresresults avera
- Page 147 and 148: 5.7. Discussion5.7. DiscussionWe ha
- Page 149 and 150: 6Sparse Linear Models Explain Pheno
- Page 151 and 152: 6.2. MethodsLasso ModelsWe used l 1
- Page 153 and 154: 6.2. Methods6.2.2. HAPGEN2 simulati
- Page 155 and 156: 6.3. Results6.2.5. Data and quality
- Page 157 and 158: 6.3. Results1005000.80.60.40.22500+
- Page 159 and 160: 6.3. ResultsDisease Abbrev. Cases C
- Page 161 and 162: 6.3. Results0.9AUC0.80.70.6DatasetB
- Page 163 and 164: 6.3. Results1.00.8PPV0.60.4●●
- Page 165 and 166: 6.3. ResultsT1D models trained on t
- Page 167 and 168: 6.4. Discussionconfidence — cases
- Page 169: 6.5. ConclusionsFrom a computationa
- Page 173 and 174: 7.2. Methods• to link the genetic
- Page 175 and 176: 7.2. Methods• Concentrations of 1
- Page 177 and 178: 7.2. Methodsreduce the degree of ov
- Page 179 and 180: 7.2. MethodsModelMarginalindependen
- Page 181 and 182: 7.3. ResultsR 20.350 0.355 0.360 0.
- Page 183 and 184: 7.3. Resultswith low R 2 . For both
- Page 185 and 186: 7.3. Resultshierarchical clustering
- Page 187 and 188: 7.3. Results0.15●R 20.100.05●
- Page 189 and 190: 7.3. ResultsR 20.70.60.50.40.30.20.
- Page 191 and 192: 7.3. Resultswith FG levels of 3.6-6
- Page 193 and 194: 7.3. Resultsalanine in the models o
- Page 195 and 196: 7.3. Resultsrs68527480.1ILMN_186713
- Page 197 and 198: 7.4. DiscussionProbe Gene λILMN 23
- Page 199: 7.4. Discussionattempt to infer cau
- Page 202 and 203: 8. Fused Multitask Penalised Regres
- Page 204 and 205: 8. Fused Multitask Penalised Regres
- Page 206 and 207: 8. Fused Multitask Penalised Regres
- Page 208 and 209: 8. Fused Multitask Penalised Regres
- Page 210 and 211: 8. Fused Multitask Penalised Regres
- Page 212 and 213: 8. Fused Multitask Penalised Regres
- Page 214 and 215: 8. Fused Multitask Penalised Regres
- Page 216: ●●●●●●●●●●●
- Page 219 and 220: ●●●●●●●●●●●
- Page 221 and 222:
●●●●●8.5. ResultsROCPRCSe
- Page 223 and 224:
8.5. ResultsTrue weightsFMPR−w1FM
- Page 225 and 226:
8.5. ResultsLassoFMPR−w2Variables
- Page 227 and 228:
8.6. DiscussionLinux. Overall, fmpr
- Page 229 and 230:
9ConclusionsA central theme of this
- Page 231 and 232:
weak effects which may exist. As da
- Page 233 and 234:
are with respect to the samples and
- Page 235 and 236:
ASupplementary Results for Gene Set
- Page 237 and 238:
A.3. External Validation0.80.80.6
- Page 239 and 240:
A.3. External Validationpamrpamr0.8
- Page 241 and 242:
A.3. External Validationvv2vv20.80.
- Page 243 and 244:
A.3. External Validationset.centroi
- Page 245:
A.3. External ValidationEstimate St
- Page 248 and 249:
B. Supplementary Results for Sparse
- Page 250 and 251:
B. Supplementary Results for Sparse
- Page 252 and 253:
B. Supplementary Results for Sparse
- Page 254 and 255:
B. Supplementary Results for Sparse
- Page 256 and 257:
B. Supplementary Results for Sparse
- Page 259 and 260:
B.2. Real Data10 10 10 10 9 8 7 7 7
- Page 261 and 262:
B.2. Real Data0.9AUC0.80.70.6Datase
- Page 263 and 264:
B.2. Real DataT1DSpecificity0.0 0.2
- Page 265 and 266:
B.2. Real DataCD1_stringentSpecific
- Page 267 and 268:
B.2. Real DataCD2_stringentSpecific
- Page 269 and 270:
B.2. Real DataAUC0.80.60.40.80.60.4
- Page 271 and 272:
B.2. Real DataFigure B.17.: Princip
- Page 273 and 274:
B.3. Results for each datasetB.3.1.
- Page 275 and 276:
B.3. Results for each datasetB.3.3.
- Page 277 and 278:
B.3. Results for each datasetB.3.4.
- Page 279 and 280:
B.3. Results for each datasetB.3.6.
- Page 281:
B.3. Results for each datasetB.3.8.
- Page 285 and 286:
Bibliography1000 Genomes Project Co
- Page 287 and 288:
BibliographyY. Benjamini and Y. Hoc
- Page 289 and 290:
BibliographyL. Chin, J. N. Andersen
- Page 291 and 292:
BibliographyVoight, H. M. Stringham
- Page 294 and 295:
BibliographyY. Freund and R. E. Sch
- Page 296 and 297:
BibliographyC. J. Hoggart, J. C. Wh
- Page 299:
BibliographyC. M. Lindgren, I. M. H
- Page 302:
BibliographyJ. D. Mosley and R. A.
- Page 305 and 306:
BibliographyE. Schneider, M. Rolli-
- Page 308 and 309:
BibliographyThe Wellcome Trust Case
- Page 310 and 311:
BibliographyS. Koduru, A. Love, F.
- Page 312:
BibliographyC. Yang, X. Wan, Q. Yan